Milestone Pharmaceuticals today announced its financial results for the fourth quarter and full year of fiscal 2025, and provided the latest updates on the commercialization progress of its innovative drug Cardamyst™ (etripamil nasal spray) for paroxysmal supraventricular tachycardia (PSVT).

The company's financial report shows that during the critical fiscal year when Cardamyst™ was approved for market launch, R&D investment and commercialization preparation funds were strategically allocated. Management emphasized that this nasal spray, as a novel self-administered treatment option for patients, has completed supply chain system construction, and the first batch of products will be delivered to distributors by the end of this quarter. In terms of financial data, fourth-quarter operating expenses focused on market access and medical education projects, and the annual cash flow reserves are sufficient to support commercialization promotion and subsequent clinical research for new indications over the next twelve months. The company's CEO stated: "The commercialization of Cardamyst™ marks a strategic step for Milestone Pharmaceuticals into the cardiovascular field, and our current funds are sufficient to accelerate market penetration." Clinical progress disclosed that phase III clinical trial data for Cardamyst™ showed the drug can rapidly terminate PSVT episodes, with an average onset time 70% shorter than traditional emergency treatments. Regulatory agencies have granted it fast review status, and the European market launch application is expected to be submitted in the first quarter of 2026. As commercialization begins, Milestone Pharmaceuticals is simultaneously expanding real-world evidence research, planning to collect patient medication data via digital platforms to optimize clinical guidelines. Analysts pointed out that this product is expected to reshape the treatment paradigm for acute PSVT attacks and seize the first-mover advantage in the $4 billions annual arrhythmia drug market.